MethylGene Announces Two Oral Presentations Highlighting Its Lead HDAC Inhibitor MCGD0103 At The American Society of Clinical Oncology Annual Meeting

MethylGene Inc. (TSX: MYG) will be presenting three abstracts, two of which are oral presentations, at the American Society of Clinical Oncology (ASCO) 2006 Annual Meeting held in Atlanta from June 2 to 6, 2006.